Home Most Popular The Rise of Mersana Therapeutics: A Glimpse into Guggenheim’s Upgrade

The Rise of Mersana Therapeutics: A Glimpse into Guggenheim’s Upgrade

0
The Rise of Mersana Therapeutics: A Glimpse into Guggenheim’s Upgrade

Guggenheim’s Positive Outlook Sparks Growth

Fintel recently divulged that on February 29, 2024, Guggenheim made a pivotal shift in their stance on Mersana Therapeutics (NasdaqGS:MRSN), upgrading the company’s status from Neutral to Buy.

Analyst Price Forecast Reveals Potential Downside

As of February 25, 2024, the average one-year price target for Mersana Therapeutics is 3.06, indicating a range from 1.01 to $5.25. This assessment forecasts a notable 43.70% decrease from the last reported closing price of 5.44.

Interested in finding out about companies with significant price target upside? Check out our leaderboard.

The estimated annual revenue for Mersana Therapeutics is 71MM, showcasing a substantial 92.06% increase. The predicted annual non-GAAP EPS stands at -1.94.

Understanding the Fund Sentiment

Currently, 238 funds or institutions hold positions in Mersana Therapeutics, denoting a decrease of 60 owners or 20.13% in the past quarter. The average portfolio weight dedicated to MRSN across all funds rests at 0.08%, exhibiting an 88.78% increase. Institutional ownership of MRSN has seen a 0.93% decline over the last three months, amounting to 117,865K shares. The put/call ratio for MRSN currently stands at 1.74, implying a bearish outlook.

Insight into Other Shareholders’ Actions

EcoR1 Capital holds 19,365K shares, accounting for 16.06% ownership with no alterations in the last quarter. VR Adviser retains 11,328K shares, reflecting 9.39% ownership, also with no recent changes.

Balyasny Asset Management currently owns 9,698K shares, constituting 8.04% ownership. Notably, the firm reported a 48.02% increase in ownership, along with a 223.45% surge in portfolio allocation towards MRSN over the previous quarter.

Bain Capital Life Sciences Investors hold 8,664K shares, possessing 7.18% ownership, with no adjustments in the last quarter. Silverarc Capital Management owns 6,420K shares, representing 5.32% ownership, with a noteworthy 22.12% increase from the earlier reported figure of 5,000K shares. The firm also boosted its portfolio allocation in MRSN by 130.27% in the past quarter.

Delving into Mersana Therapeutics
(Company Description)

Mersana Therapeutics is a dynamic clinical-stage biopharmaceutical company leveraging differentiated ADC platforms to expedite the development of innovative ADCs. Their primary product candidate, upifitamab rilsodotin (UpRi), a Dolaflexin ADC targeting NaPi2b, is currently in the expansion phase of a Phase 1 proof-of-concept clinical study involving patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, the company’s secondary ADC product candidate, is directed towards NaPi2b-expressing tumors and is undergoing dose escalation in the Phase 1 proof-of-concept clinical study. Mersana’s early-stage programs encompass XMT-1660, a Dolasynthen ADC focused on targeting B7-H4, along with XMT-2056, an STING-agonist ADC developed through the Immunosynthen platform. Additionally, numerous partners are utilizing Mersana’s Dolaflexin platform to progress their ADC pipelines.

Fintel stands as a premier investing research platform catering to individual investors, traders, financial advisors, and small hedge funds.

Our expansive data coverage spans the globe, including fundamentals, analyst reports, ownership data, fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and more. Moreover, our exclusive stock picks are bolstered by advanced, backtested quantitative models for optimized profits.

Tap here to learn more!

This article was originally published on Fintel.

The expressed views and opinions herein belong to the author and may not necessarily align with those of Nasdaq, Inc.